ReviewRadiology and oncology2023
Bleomycin electrosclerotherapy (BEST) for the treatment of vascular malformations. An International Network for Sharing Practices on Electrochemotherapy (InspECT) study group report.
Review in Radiology and oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Electrochemotherapy in pediatrics: a systematic review.European radiology · 2026Pooled it
- Simply the (B)EST: what the interventionalist needs to know about (bleomycin) electrosclerotherapy for vascular anomalies.European radiology · 2026Pooled it
- Pharmacokinetics of bleomycin in dogs treated with electrochemotherapy.The veterinary quarterly · 2026Article
- A Phalangeal Bone Lesion Managed as a Vascular Malformation: Digit-Preserving Bleomycin Electrosclerotherapy.Cardiovascular and interventional radiology · 2026Article
- Bleomycin ElectroScleroTherapy (BEST): mechanistic parallels to electrochemotherapy, experimental models, and unresolved questions.Radiology and oncology · 2026Review
- The Rising Power of Electrochemotherapy in Musculoskeletal Oncology.Current oncology (Toronto, Ont.) · 2026Review
- Case Report: Clinical management of genital, perineal, and perianal venous malformation in a five-year-old boy: therapeutic decision-making and review of current literature.Frontiers in pediatrics · 2026Article
- Prospective analysis of bleomycin electrosclerotherapy for clinical outcome and volume reduction in therapy refractory slow-flow malformations.CVIR endovascular · 2025Article
- Combining Reversible Electroporation and Bleomycin in Treatment of Arteriovenous Malformations.Cardiovascular and interventional radiology · 2025Article
- The Role of Bleomycin Sclerotherapy in Venous Malformation Management: A Narrative Review.Life (Basel, Switzerland) · 2025Review
- Bleomycin Electrosclerotherapy for Peripheral Low-Flow Venous and Lymphatic Malformations in Children: A Monocentric Case Series.Children (Basel, Switzerland) · 2025Article
- Article
- Bleomycin Electrosclerotherapy (BEST) for Slow-Flow Malformations of the Upper Aerodigestive Tract.Biomedicines · 2025Article
- Innovative Use of Bleomycin Electrosclerotherapy (BEST) for High-Flow Arteriovenous Malformations in the Head District: Preliminary Results of Two Cases.Journal of clinical medicine · 2025Article
- Tumor ablation in children.Pediatric radiology · 2025Review
- Multi-disciplinary diagnosis and management of verrucous venous malformation of the right knee: a case report.Frontiers in radiology · 2025Article
- Regimens and Response Assessment in Minimally Invasive Image-Guided Therapies for Vascular Malformations: Insights from a Large Cohort Study at a Tertiary-Care Hospital.Life (Basel, Switzerland) · 2024Article
- Outcome of bleomycin electrosclerotherapy of slow-flow malformations in adults and children.European radiology · 2024Article
- Non-clinical evaluation of pmIL12 gene therapy for approval of the phase I clinical study.Scientific reports · 2024Article
- A proposal for a revision of the phlebographic classification of congenital venous malformations.Cardiovascular diagnosis and therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 11 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiomedical applications of electroporation are expanding out of the field of oncology into vaccination, treatment of arrhythmias and now in the treatment of vascular malformations. Bleomycin is a widely used sclerosing agent in the treatment of various vascular malformations. The application of electric pulses in addition to bleomycin enhances the effectiveness of the drug, as demonstrated by electrochemotherapy, which utilizes bleomycin in the treatment of tumors. The same principle is used in bleomycin electrosclerotherapy (BEST). The approach seems to be effective in the treatment of low-flow (venous and lymphatic) and, potentially, even high-flow (arteriovenous) malformations. Although there are only a few published reports to date, the surgical community is interested, and an increasing number of centers are applying BEST in the treatment of vascular malformations. Within the International Network for Sharing Practices on Electrochemotherapy (InspECT) consortium, a dedicated working group has been constituted to develop standard operating procedures for BEST and foster clinical trials.
conclusionsBy treatment standardization and successful completion of clinical trials demonstrating the effectiveness and safety of the approach, higher quality data and better clinical outcomes may be achieved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.